Search Bar & Filters
Found 9 Actively Recruiting clinical trials
Actively Recruiting
This research aims to provide continued access to study treatments for participants with pulmonary hypertension who have completed previous clinical studies but have no other treatment alternatives. The study evaluates the long-term safety of these treatments, including macitentan, selexipag, and a fixed dose combination of macitentan and tadalafil. It is a phase 3, open-label study sponsored by Actelion. Participants who have completed parent studies and still benefit from their assigned treatment will continue receiving their study drug orally during this follow-up study. Adults typically take macitentan once daily, selexipag twice daily at their maintenance dose, or the macitentantadalafil combination once daily. Children aged 2 years and older receive doses adjusted by body weight. Study visits occur every 6 months for adults and every 3 months for pediatric participants, continuing until treatment becomes commercially available, an equivalent therapy is accessible, the participant withdraws, or the study ends early. During the study, participants undergo regular assessments to monitor safety and treatment effects, including collection of adverse event data, treatment discontinuations, serious adverse events, and deaths over up to 84 months. Visits include on-site evaluations of efficacy and safety. This long-term monitoring helps researchers understand the safety profile of these treatments when used beyond the initial clinical trials.
Actively Recruiting
Researchers are conducting a multicenter observational study in the Russian Federation focusing on patients with aggressive high-volume metastatic hormone-sensitive prostate cancer mHSPC. The study aims to analyze treatment patterns and evaluate homologous recombination repair mutations HRRm using circulating tumor DNA ctDNA. The population includes those with high-aggressive Gleason score 8-10 and high-volume disease, with known tumor HRRm status determined from routine tumor samples. Approximately 230 patients will be enrolled, equally representing HRRm and wild-type HRR HRRwt groups. This study involves no additional procedures beyond routine clinical practice. Data collection includes two visits the baseline visit gathers demographic, clinical, and treatment history from medical records and patient interviews, as well as blood samples for ctDNA and HRRm testing performed centrally. The final visit occurs at disease progression or after about 12 months to collect follow-up data on progression to metastatic castration-resistant prostate cancer mCRPC and further treatments. Follow-up data may be collected by telephone if the patient cannot visit the study site. Participants contribute data through medical record reviews, interviews, and routine blood sampling. Researchers will monitor various outcomes including treatment types and durations, progression timelines, mutation presence in ctDNA, and clinical characteristics like Gleason scores and metastasis sites. Data will be entered into electronic records, with the study lasting about 36 months until enrollment and follow-up are complete.
Actively Recruiting
Researchers are evaluating the dietary supplement Gepaktiv compared to standard medications ursodeoxycholic acid UDCA and ademetionine in adults with metabolic-associated fatty liver disease MAFLD and liver enlargement hepatomegaly. The study aims to determine if Gepaktiv can improve liver function and reduce liver size and fat accumulation as effectively as these established treatments. This is a randomized, open-label study involving 90 patients. Participants will be randomly assigned to one of three groups Gepaktiv taken as 2 capsules three times daily before meals UDCA dosed at 10-15 mgkgday or ademetionine at 800-1600 mgday. The treatment period lasts 15 days, with an optional 60-day follow-up to observe longer-term effects. Doctors will monitor liver health using blood tests, ultrasound scans, and FibroScan to assess liver enzymes, size, and fat or fibrosis levels. During the study, patients will provide daily diaries to track treatment adherence. Evaluations include blood tests for liver enzymes ALT, AST, GGT, bilirubin, lipid profile, albumin, protein levels, and quality of life questionnaires. Ultrasound and FibroScan will be performed by blinded assessors following standardized protocols. The main outcomes measured are a 30% or greater reduction in ALT, liver size decrease, and improvement in liver fat and fibrosis after 15 days, with additional follow-up assessments if participants continue. The total participation duration may extend up to 75 days including follow-up.
Actively Recruiting
Researchers are evaluating how Lipoproteina Lpa levels vary among patients with Atherosclerotic Cardiovascular Disease ASCVD in Russia and investigating the relationship between elevated Lpa levels and cardiovascular disease risk. The study aims to better understand the distribution of Lpa and its connection to cardiovascular events in this population. The study includes several phases Phase I is a cross-sectional study measuring Lpa levels in ASCVD patients aged 18 and older. Phase II involves a non-interventional, prospective cohort study with these patients and their first-degree relatives, including parents and children with elevated Lpa levels. The study observes patients and relatives over time without altering their treatments. Participants will undergo assessments to measure Lpa levels and cardiovascular events at baseline and during follow-up visits up to 24 months. Researchers will collect clinical data, including disability status, cardiovascular events, hospitalizations, and lipid-lowering therapy usage. The study monitors the percentage of patients with elevated Lpa, occurrence of cardiovascular complications, and treatment outcomes to understand the impact of Lpa levels on ASCVD progression and related health events.
Actively Recruiting
Researchers are studying the long-term safety and effectiveness of pembrolizumab MK-3475 in participants with advanced tumors or blood cancers who were part of previous pembrolizumab-based studies. This extension study includes participants currently receiving treatment or in follow-up from parent trials. It consists of three phases the First Course Phase, Survival Follow-up Phase, and Second Course Phase, depending on the participants status at the end of their previous study. Participants may receive pembrolizumab alone or combined with standard of care treatments, lenvatinib, or other study drugs like olaparib and MK-4280, delivered mainly by intravenous infusion or oral capsules. Dosing schedules vary, including pembrolizumab administered every 3 or 6 weeks for up to 35 or 17 doses depending on the phase. Some participants may take lenvatinib orally daily, timed with pembrolizumab infusions, while others may receive investigational combination therapies or standard care treatments according to their parent studys protocol. During the study, participants will have regular infusions or oral dosing and be monitored over several years for overall survival and other outcomes like progression-free survival and adverse events. Researchers will assess safety and efficacy for up to approximately 10 years, with detailed tracking of side effects and treatment discontinuations. Study visits and assessments will be conducted to evaluate organ function, disease status, and any treatment-related effects throughout the study duration.
Actively Recruiting
Researchers are evaluating the effectiveness of adjuvant ribociclib combined with hormone therapy using aromatase inhibitors with or without GnRH agonists in patients with hormone receptor-positive HR HER2-negative stage II-III breast cancer. This observational study includes two groups a prospective cohort receiving ribociclib plus aromatase inhibitors, and a retrospective cohort treated with aromatase inhibitor monotherapy. The study aims to analyze outcomes based on tumor grade, lymph node involvement, and hormone therapy response in real-world clinical practice in Russia. Participants in the prospective group receive ribociclib along with aromatase inhibitors GnRH agonists, while the retrospective group includes patients treated with aromatase inhibitor monotherapy. Data collection includes both primary prospective data and secondary retrospective data from medical records. The study does not involve experimental treatment assignments but observes existing treatment patterns and outcomes. Participants will be monitored over several years with assessments at months 36, 48, and 60 to evaluate invasive breast cancer-free survival and other related outcomes. Quality of life questionnaires and safety data including adverse events are collected at multiple time points up to 60 months. The study involves continuous data review to assess treatment adherence, disease recurrence, and patient well-being throughout the observation period.
Actively Recruiting
Researchers are studying the quality of primary health care for patients with arterial hypertension, a common condition that significantly impacts population health and mortality. This observational study uses data from a cardiovascular disease registry to analyze how well medical care aligns with current clinical recommendations. The research aims to identify trends and improve treatment approaches for patients with hypertension, including secondary forms. The study collects medical data through a computerized arterial hypertension registry with remote access, allowing online entry of patient information from outpatient records. Doctors received training to reduce data entry errors, and a user guide was provided. Patients aged 18 and older with diagnosed hypertension have their anonymized examination and treatment data added to the registry after giving informed consent. Participants involvement includes the collection of medical data from their outpatient records, which is transmitted securely and anonymously. Researchers will monitor outcomes such as the number of patients achieving blood pressure control below 14090 mm Hg and track histories of related conditions like myocardial infarction, chronic kidney disease, heart failure, and atrial fibrillation. The study also observes the use of antihypertensive medications over the period from 2018 to 2021, with ongoing data collection and analysis.
Actively Recruiting
Researchers are investigating how other existing health conditions affect the risk of complications after abdominal surgery. This observational study aims to understand the frequency and types of additional diseases among surgical patients and identify key factors that predict postoperative problems. The goal is to help better assess and manage risks for patients undergoing planned abdominal operations. The study collects information about patients age, gender, physical status by the ASA scale, presence of various diseases such as heart, lung, kidney, neurological, and metabolic conditions, and treatments they receive. It also records details about the type and severity of surgery, anesthesia methods, and uses various assessment scales related to cognition, respiratory and cardiovascular risk, liver and kidney function. Data is gathered before surgery and patients are monitored until hospital discharge. Participants provide informed consent and their data is entered into a secure database. Researchers evaluate factors influencing complications within 7 days after surgery, as well as mortality within 30 days. Statistical analysis includes regression models to identify independent risk predictors. The study involves multiple centers and follows patients throughout the hospital stay, aiming to improve understanding of postoperative risks and guide preventive strategies.
Actively Recruiting
Researchers are conducting a multicenter observational study to examine treatment methods and the presence of HER2 positive status in various stages of bladder cancer, as well as PD-L1-positive status in metastatic bladder cancer among adult patients in the Russian Federation. The study includes patients with non-muscle-invasive bladder cancer NMIBC, muscle-invasive bladder cancer MIBC, or metastatic bladder cancer mBC to better understand how these biomarkers and treatments vary by disease stage. This study does not involve any new treatments or changes to routine care. Instead, it collects information from medical records and existing tumor tissue samples obtained during standard clinical procedures. The study will include about 600 adult patients from around 30 oncology centers, divided evenly into three groups based on their bladder cancer stage. Data collection happens during a single routine clinical visit without additional follow-up. Participants provide medical history, demographic details, and information on treatments they have received. Tumor tissue samples are sent to a central laboratory for testing. Researchers will analyze these data to measure treatment patterns and biomarker prevalence, including HER2 and PD-L1 status. The study aims to complete enrollment within 18 months or once 600 patients are included, with no ongoing patient visits beyond the initial data collection.